Babazade Rovnat, Turan Alparslan
a Department of Anesthesiology , The University of Texas Medical Branch , Galveston , TX , USA.
b Department of Outcomes Research , Anesthesiology Institute , Cleveland Clinic, Cleveland , OH , USA.
Expert Opin Pharmacother. 2016 Dec;17(17):2351-2357. doi: 10.1080/14656566.2016.1254190.
Intravenous patient-controlled opioid analgesia has been an important improvement in addressing insufficient management of acute postoperative pain for over 40 years. However, there are number of weaknesses for intravenous patient-controlled analgesia, including operator and device error, intravenous line patency issues, and risk of catheter-related infection, all of which contribute to the complications and increase in cost of care. The sublingual sufentanil tablet system is a major evolution in both drug and technological management of postoperative pain. Areas covered: We reviewed the use of the sublingual sufentanil tablet system in management of moderate to severe postoperative pain in hospitalized patients, with a particular focus on the pharmacological properties of sufentanil and clinical use in different surgical patients. Expert opinion: The sublingual sufentanil tablet system can decrease intravenous opioid based patient-controlled analgesia related complications and safety issues. Current clinical studies have demonstrated this noninvasive-novel system to be safe and effective in management of acute pain in the postsurgical setting. Researchers should focus on comparing it with other available patient controlled analgesia modalities and evaluating the efficiency and cost effectiveness of the sublingual sufentanil tablet system.
四十多年来，静脉自控阿片类镇痛一直是解决急性术后疼痛管理不足的一项重要进展。然而，静脉自控镇痛存在一些缺点，包括操作和设备失误、静脉通路通畅问题以及导管相关感染风险，所有这些都会导致并发症并增加护理成本。舌下舒芬太尼片剂系统是术后疼痛药物和技术管理方面的一项重大进展。涵盖领域：我们回顾了舌下舒芬太尼片剂系统在住院患者中、重度术后疼痛管理中的应用，特别关注舒芬太尼的药理特性以及在不同手术患者中的临床应用。专家观点：舌下舒芬太尼片剂系统可减少基于静脉阿片类药物的自控镇痛相关并发症和安全问题。目前的临床研究表明，这种无创新型系统在术后急性疼痛管理中是安全有效的。研究人员应专注于将其与其他可用的自控镇痛方式进行比较，并评估舌下舒芬太尼片剂系统的效率和成本效益。
